New drug for advanced esophageal cancer after other treatments
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called Ifinatamab Deruxtecan for people with advanced esophageal squamous cell carcinoma that has progressed after one or two prior treatments. It aims to see if the drug can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that has spread or cannot be removed by surgery.
- Your cancer has gotten worse after 1 or 2 previous treatments.
- You have tumors that can be measured on scans.
- Your organs (like kidneys and liver) are working well enough.
- You do not have other serious health conditions, like uncontrolled heart disease, lung disease, or a history of lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests a new drug, Ifinatamab Deruxtecan, for people with advanced esophageal squamous cell carcinoma that has worsened after standard treatments. It aims to see if it can help shrink or slow the cancer.
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
This study tests two new drugs (gocatamig and ifinatamab deruxtecan) for people whose small cell lung cancer has spread or come back after standard chemotherapy. It aims to see if the combination works better than current options.
This study tests a new treatment for advanced or metastatic esophageal cancer that has not responded to previous chemotherapy. It aims to see if this treatment can help slow down the cancer or shrink tumors.
Hear when a new Oesophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.